

  
I hereby certify that this correspondence is being deposited with the  
United States Postal Service first class mail in an envelope  
addressed to: Commissioner for Patents  
PO Box 1450, Alexandria, VA 22313-1450, on

November 21, 2006  
BEYER WEAVER & THOMAS, LLP

By: 

Joyce L. Ferreira

Atty Docket No: 407T-895413US  
Client Ref: 1992-206-3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

**PAUL A. PRICE and JULIA S. JOHANSEN**

Application No.: 10/648,811

Filed: 08/25/2003

**For: ASSAY OF YKL-40 AS A MARKER  
FOR DEGREDDATION OF MAMMALIAN  
CONNECTIVE TISSUE MATRICES**

Examiner: Bag thuy L. Nguyen

Art Unit: 1654

Confirmation No: 5266

**DECLARATION UNDER 37 C.F.R.  
§1.132**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

I Paul A. Price hereby declare:

I, together with J. S. Johansen, M. Hansen, K. Hørslev-Petersen, and I. Lorenzen was author of the Abstract entitled, "Plasma YKL-40 Conc. In Patients With Rheumatoid Arthritis, Changes During Pulse Treatment with Methylprednisolone", Abstract for scientific conference published on or after July 12, 1992, in Davos, Switzerland, which I understand was cited as a 35 U.S.C. §102(a) reference in the above-identified patent application.

Paul A. Price (P.A. Price) and Julia S. Johansen (J.S. Johansen) are the sole inventors of the subject matter which is disclosed in the above-identified article and which is disclosed and claimed in the above-referenced patent application.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine

App. No: 10/648,811  
Page 2

or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated October 25, 2006

Paul A. Price  
Paul A. Price

c:\boms work\prosecution - current\407t uc or\407t-911230us oral peptide\407t-911230us katz.dec.doc